Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).
The company that launched the world’s first psilocybin nasal spray, Silo Wellness, is on a mission to bring healing through psychedelic and functional mushrooms with the...
The End in Mind conference will bring together celebrities, healthcare and psychedelics experts and policy makers to explore the role that psychedelics can play in the...
A new partnership between a Danish and a British startup will lead the way for advancing patient access to medical psychedelics in Europe.
Little Green Pharma has been granted a licence to supply psilocybin from the Western Australia Government Department of Health.
Novel analogues of the psychedelic compound 5-MeO-DMT have shown demonstrable safety in preclinical results.
The first-ever authorised export of GMP-compliant natural psilocybin into the US has been completed.
Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
PharmaDrug Inc.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.